University of Thessaly (UTH)
Διαγνωστική και κλινική σημασία ανοσοβιολογικών δεικτών στον καρκίνο της ωοθήκης
Abstract
dc:descriptionOvarian cancer is one of the most common gynecological malignancies. There are no specific biomarkers for early diagnosis. CA125 is used to monitor response to treatment. Paraneoplastic antibodies are produced due to the dysregulated immune response against tumor antigens. Specific immunoreactivity against tumor antigens is a promising mechanism for the development of more specific biomarkers. TRIM21/Ro52 protein is involved in inflammation, cancer and autoimmunity. In cancer it has a dual role depending on the carcinogenic factors and the type of cancer. Antibodies against Ro52/TRIM21 are frequently detected in patients with autoimmune diseases and even malignancies. In our study, sera from 77 patients with ovarian cancer were analyzed by indirect immunofluorescence, while the control group consisted of 48 patients with other types of cancer. Positivity was found in 53.2% of ovarian cancer patients with a titer ≥1/80 and with a significant proportion of these showing a cytoplasmic granular pattern of immunofluorescence. On the contrary, in the control group positivity was found in 31.2%. There was no correlation with clinical and laboratory characteristics of patients and neither with overall survival. Next, an attempt was made to find the potential target antigen in the cytoplasm by line immunotyping but it was not found to be any of the known target antigens. Subsequently, the presence of anti-Ro52 antibodies in 490 patients with various malignancies was studied and sought to map their B cell epitopes. Positivity was found in 14.3% of patients overall with the most frequent occurrence among patients with ovarian cancer (30%). A statistically significant correlation with overall survival was found. Finally, these monospecific antibodies have a different epitope profile than that seen in autoimmune rheumatic diseases. In conclusion, loss of immune tolerance against Ro52 is observed in ovarian cancer more than other types of cancer. Our study highlights the potential prognostic value of anti-Ro52 antibody in ovarian cancer patients, making it a potential future biomarker.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papadopoulos, Vasileios
- Παπαδόπουλος, Βασίλειος
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/53294